Thelansis

Sjögren’s Syndrome (SS) Market Outlook Thelansis’s “Sjögren’s Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sjögren’s Syndrome (SS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajec...

Sjögren’s Syndrome (SS) Market Outlook Thelansis’s “Sjögren’s Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sjögren’s Syndrome (SS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Sjögren’s Syndrome (SS) Overview Sjögren syndrome (SS) is a gradually progressing autoimmune disorder with various organ-specific and systemic symptoms. In SS patients, B-cell activation is consistently observed, leading to the infiltration of B and T cells into target organs, resulting in damage. The typical SS patient, most commonly perimenopausal women, experiences reduced lacrimal and salivary gland function symptoms. Common manife...

 Sjögren syndrome (SS) is a gradually progressing autoimmune disorder with various organ-specific and systemic symptoms. In SS patients, B-cell activation is consistently observed, leading to the infiltration of B and T cells into target organs, resulting in damage. The typical SS patient, most commonly perimenopausal women, experiences reduced lacrimal and salivary gland function symptoms. Common manifestations include dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca), and enlargement of the parotid glands. The oral dryness experienced by SS patients can significantly impact their quality of life, interfering with basic daily activities like eating, speaking, and sleeping. The reduction in salivary volume also reduces saliva's natural antibacterial properties, increasing the risk of infections, tooth decay, and periodontal disease. SS patients often complain of ocular discomfort, including itching, grittiness, soreness, and dryness, despite the outward appearance of no...